Cytokines and plasma factors in sickle cell disease

Current Opinion in Hematology

Volumn 14, Issue 5, 2007, Pages 438-443

  Brittain, Julia E ^a   Parise, Leslie V ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Inflammation; Leukocyte; Nitric oxide; Platelet; Pregnancy; Sickle cell disease

Indexed keywords

CYTOKINE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CYTOKINE RELEASE; GENETIC ANALYSIS; HUMAN; PATHOGENESIS; PLASMA FACTOR; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SICKLE CELL ANEMIA;

ANALGESICS, NON-NARCOTIC; ANEMIA, SICKLE CELL; ANGIOGENESIS INDUCING AGENTS; BLOOD PLATELETS; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES; NITROUS OXIDE;

EID: 34648826775     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282a4a673     Document Type: Review

References (53)

1. Parise LV, Telen MJ. Erythrocyte adhesion in sickle cell disease. Curr Hematol Rep 2003; 2:102-108.
2. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997; 100:S83-S86.
3. Okpala I. The intriguing contribution of white blood cells to sickle cell disease - a red cell disorder. Blood Rev 2004; 18:65-73.
4. Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA 2002; 99:3047-3051.
5. Barabino GA, Liu XD, Ewenstein BM, Kaul DK. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Blood 1999; 93:1422-1429.
6. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005; 19:771-784.
7. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21:37-47. In this review, the authors highlight one of the most overlooked pathologies in SCD hemolysis, and underscore its role in the depletion of NO in patients. The correlation is highlighted between hemolysis and pulmonary hypertension, priapism, leg ulceration and stroke.
8. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003; 115:721-728.
9. Makis AC, Hatzimichael EC, Bourantas KL. The role of cytokines in sickle cell disease. Ann Hematol 2000; 79:407-413.
10. Pathare A, Kindi SA, Daar S, Dennison D. Cytokines in sickle cell disease. Hematology 2003; 8:329-337.
11. Steinberg MH, Adewoye AH. Modifier genes and sickle cell anemia. Curr Opin Hematol 2006; 13:131-136.
12. Solovey A, Gui L, Ramakrishnan S, et al. Sickle cell anemia as a possible state of enhanced antiapoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood 1999; 93:3824-3830.
13. Gurkan E, Tanriverdi K, Baslamisli F. Clinical relevance of vascular endothelial growth factor levels in sickle cell disease. Ann Hematol 2005; 84:71-75.
14. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49:1015-1026.
15. Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001; 276:7614-7620.
16. Duits AJ, Rodriguez T, Schnog JJ. Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease. Br J Haematol 2006; 134:116-119. In this article, the authors studied a host of pro-angiogenic factors in SCD patients and controls and demonstrate that SCD is dominated by elevated levels of pro-angiogenic factors. Of note, this work failed to show an increase in VEGF levels during vaso-occlusive crisis, representing the heterogeneity of patient populations and quantitative methods.
17. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95:8795-8800.
18. Mohan JS, Lip PL, Blann AD, et al. The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment. Br J Ophthalmol 2005; 89:815-819.
19. Ahmad S, Hewett PW, Wang P, et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res 2006; 99:715-722. In this work, the authors provide good evidence that VEGF activates endothelial NO synthase and induces the release of NO in a human umbilical-vein endothelial cell (HUVEC) system and that this release stimulates angiogenesis.
20. Chen J, Zhang C, Jiang H, et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 2005; 25:281-290.
21. Zacharek A, Chen J, Cui X, et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab 2007 (in press).
22. Tordjman R, Delaire S, Plouet J, et al. Erythroblasts are a source of angiogenic factors. Blood 2001; 97:1968-1974.
23. Perelman N, Selvaraj SK, Batra S, et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 2003; 102:1506-1514.
24. Selvaraj SK, Giri RK, Perelman N, et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003; 102:1515-1524.
25. Litos M, Sarris I, Bewley S, Seed P, Okpala I, Oteng-Ntim E. White blood cell count as a predictor of the severity of sickle cell disease during pregnancy. Eur J Obstet Gynecol Reprod Biol 2007 (in press).
26. Tjoa ML, Levine RJ, Karumanchi SA. Angiogenic factors and preeclampsia. Front Biosci 2007; 12:2395-2402.
27. Smith JA, Espeland M, Bellevue R, et al. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol 1996; 87:199-204.
28. Croizat H, Nagel RL. Circulating cytokines response and the level of erythropoiesis in sickle cell anemia. Am J Hematol 1999; 60:105-115.
29. Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005; 128:585S-590S.
30. Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37:435-440.
31. Dhandapani KM, Brann DW. Transforming growth factor-beta: a neuroprotective factor in cerebral ischemia. Cell Biochem Biophys 2003; 39:13-22.
32. Adewoye AH, Nolan VG, Ma Q, et al. Association of polymorphisms of IGF1R and genes in the transforming growth factor- beta/bone morphogenetic protein pathway with bacteremia in sickle cell anemia. Clin Infect Dis 2006; 43:593-598. In this SNP analysis of candidate genes for susceptibility to overwhelming infection in SCD, several genes in the TGF-b family were found to be associated with bacteremia. The authors propose that these polymorphisms may help to identify a 'bacteremia-prone' phenotype in SCD.
33. Kehrl JH. Transforming growth factor-beta: an important mediator of immunoregulation. Int J Cell Cloning 1991; 9:438-450.
34. Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 2006; 213:213-227.
35. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300:729-735.
36. Nolan VG, Ma Q, Cohen HT, et al. Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B. Am J Hematol 2007; 82:179-184. In this paper polymorphisms were identified in the TGF-b family member bone morphogenetic protein receptor 1B, that may play a role in the development of renal disease in SCD.
37. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006; 133:570-578. In this SNP analysis, several genes in the TGF-β family were found to be associated with leg ulcers in SCD. The paper also demonstrated that the degree to which erythrocytes hemolyzed in SCD is a good indicator of leg ulcers.
38. Baldwin C, Nolan VG, Wyszynski DF, et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood 2005; 106:372-375.
39. Bohmer RM. Reactivation of fetal hemoglobin in adult stemcell erythropoiesis by transforming growth factor-beta. J Hematother Stem Cell Res 2003; 12:499-504.
40. Tai SC, Robb GB, Marsden PA. Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler Thromb Vasc Biol 2004; 24:405-412.
41. Wun T, Cordoba M, Rangaswami A, et al. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol 2002; 24:81-88.
42. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007 (in press).
43. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001; 137:398-407.
44. Browne PV, Mosher DF, Steinberg MH, Hebbel RP. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 1996; 51:296-301.
45. Kaul DK, Tsai HM, Liu XD, et al. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 2000; 95:368-374.
46. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 2004; 30:379-385.
47. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 96:612-616.
48. Brittain JE, Mlinar KJ, Anderson CS, et al. Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. J Clin Invest 2001; 107:1555-1562.
49. Chatila K, Ren G, Xia Y, et al. The role of the thrombospondins in healing myocardial infarcts. Cardiovasc Hematol Agents Med Chem 2007; 5:21-27. This review outlines the role of the thrombospondin family in wound healing, angiogenesis, and TGF-β activation in the context of ischemia-induced damage after myocardial infarcts. The roles for thrombospondin discussed in this review are directly applicable to SCD.
50. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000; 12:634-640.
51. Lee SP, Ataga KI, Orringer EP, et al. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006; 26:1626-1631. In this work, Lee and colleagues describe for the first time a potential role of a known inflammatory mediator - CD40L - in SCD. They document that the platelet is the origin of the elevated CD40L levels in SCD patients and illustrate the novel inflammatory role for the platelet in SCD.
52. Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52:1435-1441.
53. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14:55-61.